Comparative Pharmacology
Head-to-head clinical analysis: ALA CORT versus CORMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALA CORT versus CORMAX.
ALA-CORT vs CORMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Topical corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid, thereby reducing prostaglandin and leukotriene synthesis, and exerting anti-inflammatory, antipruritic, and vasoconstrictive effects.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive effects. Binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine release.
Topical: Apply a thin film to affected area 3-4 times daily. Dosage strength: 0.5% cream or ointment.
2.5 mg orally twice daily; maximum 10 mg/day.
None Documented
None Documented
Terminal elimination half-life: 1–2 hours for hydrocortisone (active component), prolonged in liver disease or with concurrent CYP3A4 inhibitors.
Terminal elimination half-life: 3.5 hours (range 2.5-4.5 h); clinical context: dosing every 4-6 hours to maintain therapeutic levels
Primarily hepatic metabolism (approximately 95%) followed by renal excretion of inactive metabolites (<5% unchanged). Biliary/fecal excretion is negligible.
Renal: 90% unchanged; minor biliary/fecal: <5%
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid